It is intended to provide an anticancer agent containing anti-glypican 3 antibody characterized by being administered after a treatment for cancer. The term after a treatment for cancer preferably means after a treatment for liver cancer, and after a treatment for liver cancer still preferably means after the removal of liver cancer cells. This anticancer agent is preferably employed in the case where glypican 3 is expressed in the removed liver cancer cells. It is also preferable that the anti-glypican 3 antibody is a monoclonal antibody. This anticancer agent is efficacious in preventing cancer or preventing cancer recurrence.
